Updating embryo research guidelines
With advancing lab technology perhaps calling into question a longstanding guideline that prohibits experimentation on human embryos older than 14 days, scientists and ethicists gathered at Harvard Law School recently to discuss whether and how that stricture should be revised.
Some speakers at the even urged changes that get to heart of why 14 days was once considered appropriate rather than a simple prohibition. Lifting that limit would allow scientists to learn more about human development and improve guidance on the handling of newly developed cellular structures that mimic embryos.
“My view is the 14-day rule should be looked at as a public-policy tool and not as a strict moral distinction between right and wrong,” said Insoo Hyun, associate professor of bioethics and philosophy at Case Western Reserve University. “Is it time to get rid of such lines in the sand and rely solely on clear ethical principles?”
Other speakers, however, said it’s important to understand the political ramifications of any change, ramifications that — once the guideline was opened for discussion — could see it revised in a way that many scientists wouldn’t favor.
“I’m terrified to ask lawmakers to pass laws, I’m terrified of what we’d get,” said Stanford University Law School Professor Henry Greely. “Probably worse than what we have now.”
A driving force behind the debate has been research advances that have led to the creation of self-organizing embryo-like structures (SOELS) and synthetic human embryo-like entities (SHELEs), which resemble natural human embryos in some ways.
As work continues on these embryo-like structures, some scientists question whether they should be concerned about violating the 14-day rule. Further, they said, stem cell science has enabled them essentially to fast-forward through human development to create organ-like human tissues, making calendar-based guidelines less relevant.
Because of that, some suggested rooting out factors behind the guideline — such as the ability to feel pain or to think — and using those to create guidelines more appropriate to the scientific work being done today.
“We’re making more and more faithful, more and more elaborate neural structures for any part of the brain, skipping over the body parts that may make it seem like an embryo,” said Harvard Medical School’s (HMS) Robert Winthrop Professor of Genetics George Church . “But there’s essentially no limit to the technology, so we need to focus on ethics and humanity.”
The 14-day rule is a widely accepted research guideline in the United States and is enshrined in law in a number of countries around the world. Its roots go back decades. Speakers said it was seen as appropriate because it is the point after which an embryo will not twin, and so can be considered an individual. It is also before the development of a nervous system that could allow the embryo to feel pain or think.
“What are the first appearing features of the developing embryo that signify the emergence of an entity that we should protect from experimentation?” asked John Aach, lecturer on genetics at HMS.
The event, “ The Ethics of Early Embryo Research and the Future of the 14 Day Rule ,” was sponsored by Harvard’s Edmond J. Safra Center for Ethics , the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics , the Harvard Stem Cell Institute , and Harvard’s Office of the Vice Provost for Research . It included a review of the guideline’s history, of recent progress in human developmental biology, and a panel discussion about the rule’s possible future. The event was also supported by the International Society for Stem Cell Research and HMS’ Center for Bioethics .
While Greely advised against changing the rule as it would relate to natural human embryos, he and Roger Pedersen, a professor at the University of Cambridge, were less concerned about newly developed embryo-like structures. Since they don’t have the capacity to develop on their own, Pederson said he’d create a “bright line” between them and natural human embryos with regard to the rule.
“Unless there’s a really good reason to wave the red flag in front of that bull, don’t do it,” Greely said.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
